Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05878860 · ClinicalTrials.gov registry record · Phase 1
ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis
A Phase 1 study of X-linked Retinoschisis, sponsored by Atsena Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 4
- Study locations
NCT05878860 is a Phase 1 study of X-linked Retinoschisis that is actively recruiting participants, run by Atsena Therapeutics. The registered enrollment target is 21 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT05878860, a Phase 1 study of X-linked Retinoschisis, is actively recruiting participants, sponsored by Atsena Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will evaluate the safety and tolerability of ATSN-201 in male subjects ≥ 6 years of age with RS1-associated X-linked retinoschisis (XLRS).
Conditions Studied
Interventions
- BIOLOGICAL ATSN-201
Study Locations (4)
California
- Children's Hospital of Los Angeles - Los Angeles
Florida
- Bascom Palmer Eye Institute - Miami
Oregon
- Oregon Health Sciences University - Portland
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2023-08-22 |
| Est. Completion | 2029-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05878860
The ClinicalTrials.gov registry entry for NCT05878860 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atsena Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with X-linked Retinoschisis appearing as the primary indexed condition, and to 1 intervention - of which ATSN-201 is the first listed.
NCT05878860 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Oregon.
Frequently Asked Questions
What is clinical trial NCT05878860 about?
NCT05878860 is a clinical study titled "ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis". This study will evaluate the safety and tolerability of ATSN-201 in male subjects ≥ 6 years of age with RS1-associated X-linked retinoschisis (XLRS).
What is the current status of trial NCT05878860?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2023-08-22. Estimated completion is 2029-10.
What conditions does trial NCT05878860 study?
This clinical trial studies the following conditions: X-linked Retinoschisis.
What interventions are being tested in trial NCT05878860?
The interventions under investigation include: ATSN-201 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05878860?
This trial is sponsored by Atsena Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05878860 being conducted?
This trial has 4 study locations across California, Florida, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for X-linked Retinoschisis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.